Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1929 2
1932 2
1936 1
1951 1
1952 1
1957 2
1958 2
1959 2
1961 3
1962 5
1963 4
1964 4
1965 4
1966 2
1967 6
1968 7
1969 4
1970 7
1971 6
1972 4
1973 2
1974 10
1975 10
1976 9
1977 10
1978 4
1979 8
1980 11
1981 9
1982 17
1983 17
1984 18
1985 10
1986 9
1987 10
1988 11
1989 21
1990 17
1991 25
1992 25
1993 21
1994 20
1995 27
1996 25
1997 24
1998 34
1999 37
2000 29
2001 34
2002 33
2003 41
2004 38
2005 52
2006 49
2007 60
2008 58
2009 52
2010 74
2011 94
2012 84
2013 92
2014 98
2015 113
2016 92
2017 91
2018 105
2019 105
2020 122
2021 113
2022 91
2023 77
2024 43

Text availability

Article attribute

Article type

Publication date

Search Results

2,148 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean a roselle[Author] (183 results)?
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Pérol M, Ou SI, Ahn JS, Shaw AT, Bordogna W, Smoljanović V, Hilton M, Ruf T, Noé J, Peters S. Mok T, et al. Among authors: rosell r. Ann Oncol. 2020 Aug;31(8):1056-1064. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11. Ann Oncol. 2020. PMID: 32418886 Free article. Clinical Trial.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Mazieres J, et al. Among authors: rosell r. Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167. Ann Oncol. 2019. PMID: 31125062 Free PMC article.
KRAS inhibitors, approved.
Rosell R, Aguilar A, Pedraz C, Chaib I. Rosell R, et al. Nat Cancer. 2021 Dec;2(12):1254-1256. doi: 10.1038/s43018-021-00289-3. Nat Cancer. 2021. PMID: 35121930 No abstract available.
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Mok TS, et al. Among authors: rosell r. Drugs. 2021 Feb;81(2):257-266. doi: 10.1007/s40265-020-01441-6. Drugs. 2021. PMID: 33331989 Free PMC article. Clinical Trial.
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
Chamorro DF, Cardona AF, Rodríguez J, Ruiz-Patiño A, Arrieta O, Moreno-Pérez DA, Rojas L, Zatarain-Barrón ZL, Ardila DV, Viola L, Recondo G, Blaquier JB, Martín C, Raez L, Samtani S, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Archila P, Bermudez M, Gamez T, Russo A, Malapelle U, de Miguel Perez D, de Lima VCC, Freitas H, Saldahna E, Rolfo C, Rosell R; CLICaP. Chamorro DF, et al. Among authors: rosell r. Target Oncol. 2023 May;18(3):425-440. doi: 10.1007/s11523-023-00955-9. Epub 2023 Apr 5. Target Oncol. 2023. PMID: 37017806 Free PMC article.
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).
Rosell R, Codony-Servat J, González J, Santarpia M, Jain A, Shivamallu C, Wang Y, Giménez-Capitán A, Molina-Vila MA, Nilsson J, González-Cao M. Rosell R, et al. Crit Rev Oncol Hematol. 2024 Mar;195:104228. doi: 10.1016/j.critrevonc.2023.104228. Epub 2023 Dec 9. Crit Rev Oncol Hematol. 2024. PMID: 38072173 Free article. Review.
Mechanisms of resistance to osimertinib.
Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Lazzari C, et al. Among authors: rosell r. J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30. J Thorac Dis. 2020. PMID: 32642198 Free PMC article. Review.
Docking approaches for modeling multi-molecular assemblies.
Rosell M, Fernández-Recio J. Rosell M, et al. Curr Opin Struct Biol. 2020 Oct;64:59-65. doi: 10.1016/j.sbi.2020.05.016. Epub 2020 Jun 29. Curr Opin Struct Biol. 2020. PMID: 32615514 Free PMC article. Review.
2,148 results